Impact Of Vericiguat On PA Pressures In Patients With A History Of Heart Failure And Pulmonary Hypertension

Delvin Omer,Haleigh Saari,Laura Straw,Andrew Mardis,James Ampadu

DOI: https://doi.org/10.1016/j.cardfail.2023.10.459

IF: 6.592

2024-01-01

Journal of Cardiac Failure

Abstract:Introduction There are many challenges when treating heart failure (HF), such as pulmonary hypertension (PH). The World Heart Organization (WHO) categorizes PH into five groups with group 2 PH secondary to left heart disease (LHD). The treatment for group 2 PH has focused on treating HF with guideline-directed medical therapy (GDMT) and diuretics. However, many patients with chronic heart failure may develop vascular remodeling with combined pre-and-post-capillary PH. Moreover, patients may also have comorbidities that contribute to an increase in PH. Currently, pulmonary vasodilators are contraindicated and seen as detrimental in LHD. Vericiguat (Vcgt), a soluble guanylate cyclase (sGC) stimulator has been shown to have a statistically significant reduction in the composite endpoint of cardiovascular death and/or first hospitalization for HF in the 2020 VICTORIA Trial1. Vcgt and other sGC stimulators including riociguat work by enhancing cyclic guanosine monophosphate independent of nitric oxide. This pathway has an important vasodilatory, antiplatelet aggregation, and anti-hypertrophy effects which have shown to be beneficial in the pulmonary vasculature and HF. Methods This pilot study aimed to evaluate the impact of vcgt on pulmonary artery pressure (PAP) in patients with HFrEF and WHO Group II PH. The single-center, retrospective cohort study included all patients remotely monitored with the CardioMEMs PAP monitoring system who received vcgt. PAPs were assessed at baseline prior to the initiation of vcgt and then monthly for 3 months (mo). In addition to baseline characteristics, vcgt dosing, pre- and post-vcgt echocardiography and right heart catheterization (RHC) parameters, and clinical outcomes during the study period were also collected. Continuous variables were evaluated via Student's t-test. Results A total of 13 subjects were included in the analysis. Most subjects were male, had HFrEF, and were on max tolerated GDMT. The median PAP at baseline was 56/24 (mean 36 mmHg). At each time point measured, there was no statistically significant change in the median PAP from baseline. After 3 mo of vcgt therapy, there was a modest decrease in PAP, but this difference did not reach statistical significance. Not all patients had pre-/post-vcgt echocardiography or RHC data, but there was no difference seen following initiation of vcgt. Conclusions Despite other sGC stimulators showing benefit in WHO Group I PH, vcgt did not significantly improve PAP in patients with HF and WHO Group II PH. The numerical improvement seen in this pilot study in PAP by 3 mo suggests slower improvements that warrant further extended evaluation. This evaluation is limited by retrospective data collection, smaller sample size, length of the study, and variations in GDMT.

cardiac & cardiovascular systems